Moscow, October, 20 2008

Quantum Pharmaceuticals and University of Pittsburgh announced a drug discovery collaboration in HIV sphere. Under the terms of agreement Quantum Pharmaceuticals gets access to the target data from University of Pittsburgh. Quantum Pharmaceuticals will apply its industry leading computational technology to discover novel small molecule inhibitors for this target. The University is to provide biological expertise and further develop the discovered inhibitors. The financial terms of the deal were not disclosed.
About Quantum Pharmaceuticals
Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.
About University of Pittsburgh
Founded in 1787 the University of Pittsburgh has evolved into an internationally recognized center of learning and research. The University’s 12,000 employees, including 3,800 full-time faculty members, serve about 34,000 students through the programs of 15 undergraduate, graduate, and professional schools.

Moscow, September, 28 2006

Quantum Pharmaceuticals and A.N. Belozersky Institute of Physico-Chemical Biology entered drug discovery collaboration aimed to discovery of novel small molecule inhibitors of HIV-1 integrase. HIV-1 integrase is one of the most promising targets in HIV drug discovery. Under the terms of the agreement Quantum Pharmaceuticals will apply its indystry leading drug discovery technology platform to identify novel classess of HIV-1 integrase inhibitors. The Institute is to evaluate the discovered compounds and contribute into its further research and development.

About Quantum Pharmaceuticals
Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.